trovagene.investorroom.com/...ram-on-Wednesday-October-24-2018
Trovagene to Provide Update on Onvansertib Clinical Development Program on Wednesday, October 24, 2018
"Trovagene continues to advance the development of Onvansertib, its first-in-class, 3rd generation, oral and highly-selective Polo-like Kinase 1 (PLK1) inhibitor, in leukemias, lymphomas and solid tumor cancers. The conference call will outline the status of all supported clinical studies, as well as provide an update on partnering and collaborations."
Man beachte die letzte 5 Worte :-)